A specialty pharmaceutical company that focuses on fostering industry relationships while creating strong global partnerships.
Our global partnerships help expand a portfolio of high quality products that consistently provide supply, quality and service.
Lidocaine Jelly 2% 30mL
We are pleased to announce the reintroduction of this product to the U.S. market.
Featured Products
Erythromycin
Diphenhydramine Injection
Thiamine Injection
Ampicillin
Ofloxacin
Service, quality and the industry experience and knowledge that understands what products to bring to the market.
Latest News & Articles
Armas Pharmaceuticals Announces the Reintroduction of Lidocaine Jelly 2% 30mL to the U.S. Market
FREEHOLD, N.J., March 27, 2025 /PRNewswire/ -- Armas Pharmaceuticals, a leading provider of high-quality pharmaceutical products, is pleased to announce the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market. This key product has been unavailable for more...
Armas Pharmaceuticals and Steriscience Enter Strategic Partnership to Commercialize Products for the U.S. Market
Armas Pharmaceuticals, Inc. and Steriscience have today announced an exclusive partnership for the distribution and supply of products for the U.S. market. In the first full year of collaboration, Steriscience intends to launch up to eight products through Armas...
Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now a part of Armas' consistently growing product line, bringing their portfolio count...
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
Armas Pharmaceuticals Inc. (Armas) is announcing the launch of generic Tarceva® (a trademark of Genentech USA, Inc) Tablets. Erlotinib is now available in 25mg, 100mg and 150mg strengths. This is Armas' third oral solid to be added to their oncology portfolio. "I am...